Araris Biotech AG is a spin-off company of PSI and ETH Zurich, which is engaged in the development of novel antibody-drug compounds for the targeted therapy of cancer cells. The company has successfully closed a financing round in the amount of 24 million US dollars. Proceeds from the financing round, which was led by 4BIO Capital and Pureos Bioventures with participation from new investors, will be used to further develop Araris' antibody-drug conjugate (ADC) candidates. Araris is thus one step closer to its goal of helping cancer patients better and more effectively.
Dr. Philipp Spycher, CEO of Araris Biotech AG began his entrepreneurial endeavors with the PSI Founder Fellowship that helped kick-start his ideas of building a business around the technology that he helped to develop at PSI.
We are delighted with the success of Araris and congratulate the team warmly on this milestone!
